The Department of Medicine

Radhakrishnan Ramchandren, MD

Professor
Chief, Division of Hematology/Oncology
Division of Hematology and Oncology

Research Focus

Dr. Ramchandren's major research interest involves the identification and development of novel agents for the treatment of Hodgkin's and Non-Hodgkin's lymphoma. In addition, a series of correlative and biomarker-based projects are being designed to identify which patients benefit from novel cancer therapeutics.

Education

Medical School
Ross University School of Medicine, Dominica, 2001

Residency
Internal Medicine-Drexel University College of Medicine-Hahnemann University, Philadelphia, PA, 2004

Fellowship
Hematology-Oncology-St. John Health-Providence Hospital, Southfield, MI, 2008

Certifications

American Board of Internal Medicine, 2006
American Board of Internal Medicine - Medical Oncology, 2008
American Board of Internal Medicine - Hematology, 2009

Professional Affiliations

American Society of Hematology
American Society of Clinical Oncology
American College of Physicians

Current Publications

Wall JS, Martin EB, Lands R, Ramchandren R, Stuckey A, Heidel RE, Whittle B, Powell D, Richey T, Williams AD, Foster JS, Guthrie S, Kennel SJ..
Cardiac amyloid detection by PET/CT imaging of iodine ((124)i) evuzamitide ((124)i-p5+14): A phase 1/2 study. JACC Cardiovasc Imaging. 2023 Nov;16(11):1433-1448. doi: 10.1016/j.jcmg.2023.08.009.

Mei M, Perini G, Ramchandren R.
Editorial: Advances in the treatment of hodgkin lymphoma. Front Oncol. 2023 Feb 28;13:1164081. doi: 10.3389/fonc.2023.1164081. eCollection 2023.

Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, et al.
Overall survival with brentuximab vedotin in stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13.

Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, et al.
Overall survival with brentuximab vedotin in stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13.

Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Ramchandren R, et. al.
Outcomes among classical Hodgkin Lymphoma patients after an Interim PET scan: A real-world experience. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e435-e442. doi: 10.1016/j.clml.2021.12.012. Epub 2021 Dec 25.

Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Ramchandren R, et. al.
Outcomes among classical Hodgkin Lymphoma patients after an Interim PET scan: A real-world experience. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e435-e442. doi: 10.1016/j.clml.2021.12.012. Epub 2021 Dec 25.

Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A.
Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & Lymphoma. 2021 Nov 15:1-8. [Epub ahead of print]

Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A.
Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & Lymphoma. 2021 Nov 15:1-8. [Epub ahead of print]

Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A.
Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & Lymphoma. 2021 Nov 15:1-8. [Epub ahead of print]

Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald AB, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla JG.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances. 2021 Oct 13:bloodadvances.2021004970. [Epub ahead of print]

Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS.
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: The safety run-in of the phase 3 SYMPATICO study. Journal of Hematology & Oncology. 2021 Oct 30;14(1):179.

Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki Y.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: Report of a phase 2 trial and exploratory biomarker analyses. British Journal of Haematology. 2021 Aug 2. [Epub ahead of print]

Straus DJ, Dlugosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J.
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. The Lancet. Haematology. 2021 Jun;8(6):e410-e421.

Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021 Apr 7:blood.2020009178. [Epub ahead of print]

Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M.
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Mar 3. [Epub ahead of print]

Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, K.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Advances. 2021 Mar 23;5(6):1648-1659.

Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar .
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet. Oncology. 2021 Mar 12:S1470-2045(21)00005-X. [Epub ahead of print]

Seymour E, Khan HY, Li Y, Chaker M, Muqbil I, Aboukameel A, Ramchandren R, Houde C, Sterbis G, Yang J, Bhutani D, Pregja SL, Reichel KA, Huddlestun A, Neveux C, Corona K, Landesman Y, Shah J, Kauffman M, Shacham S, Mohammad RM, Azmi AS, Zonder J.
Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: Results of a phase 1 study. Clinical Cancer Research. 2021 Mar 30:clincanres.4929.2020. [Epub ahead of print]